Conflicting evidence from late-stage clinical work has knocked Chelsea Therapeutics over once again. The FDA has sent its lead product Northera back for more work, saying the product needs additional supporting study and to demonstrate durability of treatment effect in patients with dangerously low blood pressure.Shares in the North Carolina company fell sharply on the news, down 26% to $2.73 in early trading today. Executives said an ongoing 10-week trial of Parkinson’s disease patients could be amended to meet the FDA’s request for up to three months of data, but the decision will delay approval of the agent until 2013. With only enough cash to last until early 2013, Chelsea is in a tight spot.
This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: email@example.com
EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.
Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
Terms & Conditions